Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics

Autolus Therapeutics plc - American Depositary Share (AUTL): $1.99

0.11 (+5.85%)

POWR Rating

Component Grades













Add AUTL to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where AUTL ranks best; there it ranks ahead of 74.89% of US stocks.
  • The strongest trend for AUTL is in Value, which has been heading up over the past 177 days.
  • AUTL ranks lowest in Momentum; there it ranks in the 5th percentile.

AUTL Stock Summary

  • Of note is the ratio of AUTOLUS THERAPEUTICS PLC's sales and general administrative expense to its total operating expenses; merely 6.78% of US stocks have a lower such ratio.
  • With a price/sales ratio of 62.43, AUTOLUS THERAPEUTICS PLC has a higher such ratio than 96.75% of stocks in our set.
  • AUTOLUS THERAPEUTICS PLC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -64.6%, greater than the shareholder yield of merely 8.32% of stocks in our set.
  • Stocks that are quantitatively similar to AUTL, based on their financial statements, market capitalization, and price volatility, are GRTS, PSTX, CNCE, LPTX, and ABUS.
  • AUTL's SEC filings can be seen here. And to visit AUTOLUS THERAPEUTICS PLC's official web site, go to

AUTL Valuation Summary

  • In comparison to the median Healthcare stock, AUTL's price/sales ratio is 3173.17% higher, now standing at 67.1.
  • Over the past 56 months, AUTL's price/earnings ratio has gone up 46.8.

Below are key valuation metrics over time for AUTL.

Stock Date P/S P/B P/E EV/EBIT
AUTL 2023-01-20 67.1 1.1 -1.1 -0.2
AUTL 2023-01-19 63.8 1.1 -1.1 -0.1
AUTL 2023-01-18 63.3 1.1 -1.1 -0.1
AUTL 2023-01-17 67.5 1.1 -1.1 -0.2
AUTL 2023-01-13 70.5 1.2 -1.2 -0.2
AUTL 2023-01-12 66.8 1.1 -1.1 -0.2

AUTL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AUTL has a Quality Grade of F, ranking ahead of 4.94% of graded US stocks.
  • AUTL's asset turnover comes in at 0.008 -- ranking 401st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AUTL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.008 1 -1.381
2021-06-30 0.009 1 -1.295
2021-03-31 0.005 1 -1.315
2020-12-31 0.005 1 -1.295
2020-09-30 0.005 1 -1.458
2020-06-30 0.004 1 -1.587

AUTL Stock Price Chart Interactive Chart >

Price chart for AUTL

AUTL Price/Volume Stats

Current price $1.99 52-week high $5.04
Prev. close $1.88 52-week low $1.60
Day low $1.83 Volume 655,400
Day high $2.01 Avg. volume 494,642
50-day MA $2.13 Dividend yield N/A
200-day MA $2.69 Market Cap 344.39M

Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio

Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.

AUTL Latest News Stream

Event/Time News Detail
Loading, please wait...

AUTL Latest Social Stream

Loading social stream, please wait...

View Full AUTL Social Stream

Latest AUTL News From Around the Web

Below are the latest news stories about AUTOLUS THERAPEUTICS PLC that investors may wish to consider to help them evaluate AUTL as an investment opportunity.

Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?

Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

Yahoo | January 24, 2023

Is Autolus Therapeutics (NASDAQ:AUTL) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | January 23, 2023

Autolus Therapeutics announces Board changes

LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two changes to the company’s Board of Directors. The company’s non-executive Chairman, John H Johnson, who has held the role since September 2021, will not stand for re-election at Autolus’ upcoming annual shareholder meeting. During his tenure as Chairman of Autolus he was appointed as Chief Executive Offi

Yahoo | January 20, 2023

Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CABA). The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety switch1 into a cell therapy program for the treatment of autoimmune disease, with an option for Cabaletta to incorporate the

Yahoo | January 9, 2023

Individual investors account for 36% of Autolus Therapeutics plc's (NASDAQ:AUTL) ownership, while private equity firms account for 32%

If you want to know who really controls Autolus Therapeutics plc ( NASDAQ:AUTL ), then you'll have to look at the...

Yahoo | December 26, 2022

Read More 'AUTL' Stories Here

AUTL Price Returns

1-mo 4.74%
3-mo -28.42%
6-mo -38.77%
1-year -50.13%
3-year -79.74%
5-year N/A
YTD 4.74%
2022 -63.39%
2021 -41.95%
2020 -32.27%
2019 -59.81%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7487 seconds.